IP Library Granted Patent US 9,476,031
Granted Patent B2
US 9,476,031 · App. 14/009,662 · Granted Oct 25, 2016

Method for rejuvenating cells

Inventors: Alexandre Prieur (Montpellier, FR); Ollivier Milhavet (Montpellier, FR); Jean-Marc Lemaitre (Montpellier, FR); Laure Lapasset (Montpellier, FR)
Assignees: Institut National de la Santé et de la Recherche Médicale (INSERM); CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS); UNIVERSITE MONTPELLIER I; UNIVERSITE MONTPELLIER II
C12N5/0696A61K35/12C12N2501/602C12N2501/603C12N2501/604C12N2501/605C12N2501/606C12N2501/608
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,476,031
App. No.
14/009,662
Granted
Oct 25, 2016
Kind
B2
Abstract

The invention relates to a method for reprogramming cells from aged donors or senescent cells to pluripotent cells that have lost marks of senescence. In particular, the invention relates to an ex vivo method for preparing induced pluripotent stem cells (iPSCs) from a target cell population comprising cells from aged donors or senescent cells, said method comprising the steps of culturing said target cell population under appropriate conditions for reprogramming said cells into iPSCs, wherein said appropriate conditions comprises increasing expression in said target cells, of at least the following reprogramming factors: Oct4, Klf4, Sox2, c-Myc, Lin28 and, optionally Nanog.

Claims (31)

1. An ex vivo method for preparing rejuvenated induced pluripotent stem cells (iPSCs) from senescent cells, said method comprising the steps of:

a) providing said senescent cells and,

b) culturing said target cell population under appropriate conditions for reprogramming said target cell population into iPSCs, wherein said appropriate conditions comprise increasing expression in said target cell population, of at least the following combination of reprogramming factors:

i. a reprogramming factor encoded by one gene of the Oct gene family,

ii. a reprogramming factor encoded by one gene of the Klf gene family,

iii. a reprogramming factor encoded by one gene of the Sox gene family, iv. a reprogramming factor encoded by one gene of the Myc gene family,

v. Lin28,

vi. and Nanog,

wherein the method results in preparation of rejuvenated iPSC cells in which the expression of p21 CIPI and p16 IN1K4A is downregulated to a level found in human embryonic stem cells (hESC).

2. The method of claim 1 , wherein said combination of reprogramming factors comprises Oct4, Klf4, Sox2, c-Myc, Lin28 and Nanog.

3. The method of claim 1 , wherein said senescent cells are:

a. human senescent cells;

b. human senescent cells obtained from an adult subject that is at least 50 years old; or

c. human senescent cells obtained from a subject suffering from age-related disorders leading to a high proportion of senescent cells.

4. The method of claim 1 , wherein said method does not further comprise a step of silencing senescence effectors in said senescent cells.

5. The method of claim 4 , wherein said senescence effectors include p21 CIP and/or p16 INK4a and/or p53.

6. The method according to claim 1 , wherein said conditions for increasing expression of the reprogramming factors comprise

a) introducing one or more expression vectors comprising coding sequences of said combination of reprogramming factors into said senescent cells; or,

b) directly delivering an effective amount of each precursor RNA of the reprogramming factors into said senescent cells.

7. The method of claim 6 , wherein said step of introducing is performed by transfecting said senescent cells with said one or more expression vectors.

8. An in vitro method for rejuvenating senescent cells, said method comprising the step of

reprogramming said cells to induced pluripotent stem cells iPSCs, by increasing expression in said cells of at least a combination of the following reprogramming factors:

i. a reprogramming factor encoded by one gene of the Oct gene family,

ii. a reprogramming factor encoded by one gene of the Klf gene family,

iii. a reprogramming factor encoded by one gene of the Sox gene family,

iv. a reprogramming factor encoded by one gene of the Myc gene family, Lin28,

v. and Nanog.

9. The method of claim 8 , wherein said step of reprogramming includes a step of culturing said cells under appropriate conditions for increasing expression of the following reprogramming factors: Oct4, Klf4, Sox2, c-Myc, Lin28 and Nanog.

10. The method of claim 3 , wherein said human senescent cells are human fibroblast senescent cells.

11. The method according to claim 1 , wherein said senescent cells provided at step (a) are comprised in a cell composition obtained from an adult subject that is at least 50 years old.

12. The method of claim 8 , wherein said senescent cells are comprised in a cell composition obtained from an adult subject that is at least 50 years old.

Assignments (2)
MERGER Recorded Aug 9, 2018
From: UNIVERSITÉ DE MONTPELLIER I; UNIVERSITÉ MONTPELLIER 2 SCIENCES ET TECHNIQUES
To: UNIVERSITÉ DE MONTPELLIER
Reel/Frame 046604/0873 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 31, 2013
From: PRIEUR, ALEXANDRE; MILHAVET, OLLIVIER; LEMAITRE, JEAN-MARC; LAPASSET, LAURE
To: INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE); CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS); UNIVERSITE MONTPELLIER I; UNIVERSITE MONTPELLIER II
Reel/Frame 031518/0455 →
Priority Claims (1)
EP 11161771 · Apr 8, 2011 · regional
Continuity (1)
Related Publication 20140056860A1 · Feb 27, 2014